Lipum gets approval to start Phase 1 clinical trial with drug candidate SOL-116

Press release: Umeå, 27 September, 2022. Lipum AB (publ) announces today that the CTA (clinical trial application) for the drug candidate SOL-116 has been approved by the regulatory authorities in The Netherlands.

The release as fetched from its publisher. lipum.se ↗